23378 Allo U.S. Homepage Banner

Join the Allogeneic Cell Therapies Summit to Transform a Universal Cell Therapy!

Allogeneic therapies are game changing in the field of cell therapy, overcoming current critical barriers around cost, production, and accessibility currently faced with autologous, personalized treatments. With billions of pounds worth of investment seen in collaborations to advance the development of allogeneic CAR-T, NK, macrophage and iPSC-based therapies, the excitement in this space is explosive!

Capitalizing on this “holy grail” approach at the 4th Allogeneic Cell Therapies Summit, the leading industry-focused meeting captured cutting-edge advances across pre-clinical development, translation, manufacturing, supply and storage, to accelerate the successful clinical translation of your allogeneic pipeline.

This fast-evolving community compared and contrasted platform technology to improve durability and persistence, review the strategies for selecting gold-standard donor starting material, and learnt about the latest developments in gene engineering and serve as the “off-the-shelf” ready-to-use therapeutic agents for large-scale clinical applications.

Over 300 experts from pharma, biotech and leading academia united in Boston to collaborate and share lessons learned to streamline scalable manufacturing processes, define optimal cryopreservation conditions and define regulatory expectations to achieve the huge demand for these treatments.

2022 showcased the work of Allogene, Atara Biotherapeutics, Cellectis, Celularity, ImmunityBio, and more, don’t miss out on the most important meeting of the cell therapy calendar in 2023.

What You Can Expect at Allogeneic Cell Therapies Summit 2022:

23378 Allo U.S. Stats